Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Personalized Medicine and Inhibition of<i>EGFR</i>Signaling in Lung Cancer

20 Aug 2009

Abstract excerpt

The concept underlying much of cancer therapy is that patients with specific types and stages of cancer should be treated according to standardized, predetermined protocols. However, recent advances in drug development, pharmacogenomics, and the molecular characterization of tumors — including genomewide RNA expression, DNA copy-number and sequence analyses, and microRNA and proteomic profiling — have the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Lung Cancer Treatments and Mutations
Share to RNA modifications and cancer

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19692681
DOI: 10.1056/nejme0905763

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 10 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Personalized Medicine and Inhibition of<i>EGFR</i>Signaling in Lung CancerPMID 19692681Read ↗

Cellular Origins of EGFR‐Driven Lung Cancer Cells Determine Sensitivity to TherapySemantic proximity Read ↗

Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies.Semantic proximity Read ↗

Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment.Semantic proximity Read ↗

Reversible therapeutic resistance in <i>EGFR</i> mutant lung cancer caused by <i>RB1</i> loss induced lineage plasticitySemantic proximity Read ↗

EGFR inhibitors: what have we learned from the treatment of lung cancer?Semantic proximity Read ↗

Complementary modes of resistance to <i>EGFR</i> TKI in lung adenocarcinoma through MAPK activation and cellular plasticitySemantic proximity Read ↗

A Closer Look at EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer through the Lens of Precision MedicineSemantic proximity Read ↗

Epidermal growth factor receptor (EGFR) signaling and covalent EGFR inhibition in lung cancer.Semantic proximity Read ↗

Another Slice of the Pie Uncovered: RIT1M90I Is an Actionable Driver in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Personalized medicine of non-gene-specific chemotherapies for non-small cell lung cancerSemantic proximity Read ↗

Personalized therapy for non-small cell lung cancer: hype or clinical reality?Semantic proximity Read ↗

Patient-derived cell-based pharmacogenomic assessment to unveil underlying resistance mechanisms and novel therapeutics for advanced lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.